Compare GROV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | ACRV |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 47.6M |
| IPO Year | N/A | 2022 |
| Metric | GROV | ACRV |
|---|---|---|
| Price | $1.34 | $1.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.60 | ★ $13.00 |
| AVG Volume (30 Days) | 75.4K | ★ 864.7K |
| Earning Date | 03-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | $691.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $1.05 |
| 52 Week High | $1.66 | $5.65 |
| Indicator | GROV | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 49.01 |
| Support Level | $1.29 | $1.49 |
| Resistance Level | $1.46 | $1.86 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 70.59 | 66.18 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.